Intercell completed the acquisition of Cytos' antibody technology platform

09-Jun-2010 - Austria

Intercell AG announced the closing of the acquisition of Cytos' platform technology for monoclonal antibody discovery. Intercell had announced the intent to acquire that technology, which is based on Expression cloning of monoclonal antibodies from human B‐cells, for EUR 15m. The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®).

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous